Monte Rosa Therapeutics (GLUE) Operating Expenses (2020 - 2026)

Monte Rosa Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $54.2 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 32.65% year-over-year to $54.2 million in Q1 2026; TTM through Mar 2026 was $191.2 million, a 18.32% increase from a year earlier, with the FY2025 full-year figure at $177.9 million, up 13.49% from the prior year.
• Operating Expenses rose to $54.2 million in Q1 2026 per GLUE's latest filing, from $52.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $54.2 million in Q1 2026 and bottomed at $24.3 million in Q1 2022.
• The 5-year median for Operating Expenses is $37.0 million (2023), against an average of $37.9 million.
• Across the five-year window, Operating Expenses jumped 111.25% in 2022 and slipped 3.31% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $32.5 million in 2022, then climbed by 7.31% to $34.9 million in 2023, then surged by 36.66% to $47.6 million in 2024, then increased by 10.19% to $52.5 million in 2025, then increased by 3.33% to $54.2 million in 2026.
• Per Business Quant, the three latest GLUE Operating Expenses figures stand at $54.2 million (Q1 2026), $52.5 million (Q4 2025), and $45.7 million (Q3 2025).